iTANK: A universal CAR/TCR T-cell enhancement platform, compatible with any CAR/TCR T-cell-cell therapy for a multi-targeted attack on solid tumors

iTANK is a universal CAR/TCR T-cell enhancement technology platform that arms CAR/TCR T-cells with a pluripotent proinflammatory neutrophil- activating protein (NAP) from Helicobacter pylori, which induces bystander immunity via epitope spreading. Preclinical data, published in Nature Biomedical Engineering, have demonstrated:

• Compatibility with ANY CAR/TCR T-cell therapies
• Broad attack on multiple targets across blood cancer AND solid tumors
• Efficient and durable CAR/TCR T-cells
• No added toxicity

Proof-of-concept data was published in Nature Biomedical Engineering in April 2022. Download the publication to learn more about iTANK, its mode of action and how it can enhance your immunotherapy research!

* immunoTherapies Activated with NAP for efficient Killing

Based in Sweden, Elicera Therapeutics AB is a clinical stage immuno-oncology company developing next generation cell and gene therapies for immune-based cancer treatments.

In addition to the iTANK platform, Elicera is developing four drug candidates, two of which are in the field of oncolytic viruses and two in the field of CAR T-cell therapies. Please contact us via the form below with any enquiries.